Evolving role of immunotherapy in head-and-neck cancers: A systemic review

Chanana, Raajit; Noronha, Vanita; Joshi, Amit; Patil, Vijay; Prabhash, Kumar

doi:10.4103/jhnps.jhnps_10_18

Cited by 8 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, one patient in the HNSCC cohort and three in the NSCLC cohort achieved immune SD following previous progression per RECIST. The observation of pseudoprogression (disease progression per RECIST followed by subsequent reduction in tumor burden) [26] in several patients enrolled in this study is characteristic of immune checkpoint inhibitors, and similar observations have been reported in studies of other immune checkpoint inhibitors, including ipilimumab, nivolumab, and pembrolizumab [27][28][29][30]. Durable responses were observed both in PD-L1 + and PD-L1-patients in the current study, similar to responses observed in clinical studies of other PD-1-targeting agents [21,22].…”

Section: Discussionsupporting

confidence: 85%

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

Italiano

Cassier

Lin

et al. 2021

Cancer Immunol Immunother

View full text Add to dashboard Cite

Background Budigalimab is a humanized, recombinant immunoglobulin G1 monoclonal antibody targeting programmed cell death protein 1 (PD-1). We present the safety, efficacy, pharmacokinetic (PK), and pharmacodynamic data from patients enrolled in the head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) expansion cohorts of the phase 1 first-in-human study of budigalimab monotherapy (NCT03000257; registered 15 December 2016). Patients and methods Patients with recurrent/metastatic HNSCC or locally advanced/metastatic NSCLC naive to PD-1/PD-1-ligand inhibitors were enrolled; patients were not selected on the basis of oncogene driver mutations or PD-L1 status. Budigalimab was administered at 250 mg intravenously Q2W or 500 mg intravenously Q4W until disease progression/unacceptable toxicity. The primary endpoints were safety and PK; the secondary endpoint was efficacy. Exploratory endpoints included biomarker assessments. Results In total, 81 patients were enrolled (HNSCC: N = 41 [PD-L1 positive: n = 19]; NSCLC: N = 40 [PD-L1 positive: n = 16]); median treatment duration was 72 days (range, 1–617) and 71 days (range, 1–490) for the HNSCC and NSCLC cohorts, respectively. The most frequent grade ≥ 3 treatment-emergent adverse event was anemia (HNSCC: n = 9, 22%; NSCLC: n = 5, 13%). Both dosing regimens had comparable drug exposure and increased interferon gamma-induced chemokines, monokine induced by gamma interferon, and interferon-gamma-inducible protein 10. Objective response rates were 13% (90% CI, 5.1–24.5) in the HNSCC cohort and 19% (90% CI, 9.2–32.6) in the NSCLC cohort. Median progression-free survival was 3.6 months (95% CI, 1.7–4.7) and 1.9 months (95% CI, 1.7–3.7) in the HNSCC and NSCLC cohorts. Conclusions The safety, efficacy and biomarker profiles of budigalimab are similar to other PD-1 inhibitors. Development of budigalimab in combination with novel anticancer agents is ongoing.

show abstract

Section: Discussionsupporting

confidence: 85%

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

Italiano

Cassier

Lin

et al. 2021

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…These breakthroughs empower researchers to better unravel the molecular underpinnings of diseases and pinpoint potential molecular targets for intervention. 1 Current oncology trends include therapeutics (precision medicine, immunotherapy, and targeted therapy), [2][3][4][5][6][7] patient-centred care, 8 multidisciplinary care, 9 and technology in oncology care. 10 Oncology and palliative care (PC) have traditionally been closely intertwined.…”

Section: Introductionmentioning

confidence: 99%

Barriers And Challenges Of Multidisciplinary Teams In Oncology Management: A Scoping Review Protocol

Law,

Hong,

Tan

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionMultidisciplinary teams (MDTs) are integral to oncology management, involving specialised healthcare professionals who collaborate to develop individualised treatment plans for patients. However, as cancer care grows more complex, MDTs must continually adapt to better address patient needs. This scoping review will explore barriers and challenges MDTs have encountered in the past decade; and propose strategies for optimising their utilisation to overcome these obstacles and improve patient care.Methods and analysisThe scoping review will follow Arksey and O’Malley’s framework and begin with a literature search using keywords in electronic databases such as PubMed/MEDLINE, Scopus and PsychINFO, covering the period from January 2013 to December 2022 and limited to English language publications. Four independent reviewers will screen titles and abstracts based on predefined inclusion criteria, followed by full-text review of selected titles. Relevant references cited in the publications will also be examined. A Preferred Reporting Items for Systematic reviews and Meta-Analyses flow diagram will be utilised to illustrate the methodology. Data from selected publications will be extracted, analysed, and categorised for further analysis.Ethics and disseminationThe results of the scoping review will provide a comprehensive overview of the barriers and challenges encountered by oncology MDTs over the past decade. These findings will contribute to the existing literature and provide insights into areas that require improvement in the functioning of MDTs in oncology management. The results will be disseminated through publication in a scientific journal, which will help to share the findings with the wider healthcare community and facilitate further research and discussion in this field.Trial registration detailsThe protocol for this scoping review is registered with Open Science Framework, available at DOI 10.17605/OSF.IO/R3Y8U.

show abstract

“…Head-and-neck squamous cell cancers (HNSCCs) are one of the most common cancers worldwide. [ 1 ] The treatment of HNSCC varies by tumor site and stage, however the standard treatment include surgery, radiation and cytotoxic chemotherapy. [ 2 ] Despite advances in treatment, more than half of all cancers recur locoregionally or distantly.…”

Section: Introductionmentioning

confidence: 99%

“…Immunotherapy is designed to either actively target a specific antigen on the tumor or enhance the host's immune system. [ 1 5 ]…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy

Sahu

Suryawanshi

2021

Journal of Oral and Maxillofacial Pathology

View full text Add to dashboard Cite

Head and neck squamous cell carcinomas (HNSCCs) are one of the most common cancers worldwide. A large number of patients are diagnosed with locally advanced disease and require multimodal treatment approaches. Standard treatment modalities ranging from surgery to chemotherapy and radiation are yielding mixed results. To overcome this hurdle, newer innovative approaches are required to reduce the morbidity and mortality of the patients. In the last few decades, immunotherapy has become an important part of treating some types of cancer. The immune system plays a key role in the development, establishment and progression of HNSCC. A greater understanding of the dysregulation and evasion of the immune system in the evolution and progression of HNSCC provides the basis for improved therapies and outcomes for patients. Newer types of immune treatments are now being studied, and they will impact how we treat cancer in the future. This article provides a brief overview of the current immunotherapeutic strategies for cancer with emphasis on HNSCC.

show abstract

Evolving role of immunotherapy in head-and-neck cancers: A systemic review

Cited by 8 publications

References 8 publications

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

Barriers And Challenges Of Multidisciplinary Teams In Oncology Management: A Scoping Review Protocol

Immunotherapy

Contact Info

Product

Resources

About